Latest Breaking News On - Clare gidley - Page 4 : comparemela.com

U S FDA Approves Blue Earth Diagnostics POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

- POSLUMA will be commercially available in the United States in early June 2023 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative

United kingdomUnited statesClare gidleyMike beyerPriscilla harlanShelby moneerDavidm schusterBrianf chapinScintomics gmbDavide gaudenTechnical university of munichNuclear medicineDrug administrationDepartment of urologyEmory university school of medicineCorporate communications

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesScintomics gmbBriant helfandDavide gaudenMike beyerPriscilla harlanClare gidleyNuclear medicineStudy groupDivision of urologyBracco groupNorthshore university healthsystemTechnical university of munichDrug administrationCorporate communications

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer

MONROE TOWNSHIP, N.J. & OXFORD, England (BUSINESS WIRE) Apr 29, 2023

United statesUnited kingdomBriant helfandMike beyerPriscilla harlanClare gidleyScintomics gmbDavide gaudenDivision of urologyTechnical university of munichNuclear medicineAmerican urological associationDrug administrationStudy groupCorporate communicationsSam brown inc

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent ¹⁸F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent ¹⁸F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesClare gidleyDavide gaudenBriant helfandPriscilla harlanMike beyerScintomics gmbBracco groupSam brown incDivision of urologyTechnical university of munichNuclear medicineNorthshore university healthsystemDrug administrationCorporate communications

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 SPOTLIGHT Study of PET Imaging Agent 18F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer

- Results to be presented at American Urological Association's 2023 Annual Meeting (AUA2023) - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization

Mccormick placeUnited statesUnited kingdomPriscilla harlanScintomics gmbBriant helfandMike beyerClare gidleyNorthshore university healthsystemBracco groupAmerican urological associationNuclear medicineStudy groupCorporate communicationsCompany at boothDivision of urology